Valuation : Kamada Ltd.

Market Cap 1.46B 0 487M 419M 393M 360M 671M 46.01B 676M 4.65B 1.81B 23.51B 1.83B 1.79B 75.72B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.46B 0 487M 419M 393M 360M 671M 46.01B 676M 4.65B 1.81B 23.51B 1.83B 1.79B 75.72B EV / Sales 2026 *
2.42x
EV / Sales 2027 * 2.17x
Free-Float
54.48%
Yield 2026 *
-
Yield 2027 * -
1 day-2.25%
1 week+2.14%
Current month+1.22%
1 month+12.83%
3 months+16.76%
6 months-11.27%
Current year+9.73%
1 week 2,400
Extreme 2400
2,546
1 month 2,013
Extreme 2013
2,578
Current year 2,013
Extreme 2013
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 58 2015-06-30
Director of Finance/CFO 56 2017-12-30
Chief Operating Officer 54 2016-10-31
Director TitleAgeSince
Director/Board Member 75 1990-12-12
Chairman 77 2013-03-06
Chairman 55 2020-08-11
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 Exercice

VP Quality

68,328 0.1184%
8/5/26 Free

Director

30,000 0.0520%
8/5/26 Free

Chairman

30,000 0.0520%
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%+2.14%+4.77%+14.34% 484M
-0.80%+4.76%+50.09%+2.83% 85.08B
-4.55%+0.85%+498.67%+31.66% 60.21B
+0.95%+1.77%-15.77%-34.78% 59.71B
-1.60%-7.63%-3.65%+31.05% 51.1B
+0.09%-0.54%+9.26%+170.07% 48.73B
+0.67%+1.12%+58.16%-15.88% 32.9B
-0.19%+0.68%+47.90%+103.24% 26.11B
+0.79%-6.56%-2.56%+192.31% 22.6B
+1.10%-1.67%+64.17%+113.16% 16.42B
Average -0.58%-1.24%+71.10%+60.80% 40.34B
Weighted average by Cap. -0.78%-0.78%+93.64%+45.44%

Financials

2026 *2027 *
Net sales 606M 0 201M 173M 163M 149M 278M 19.05B 280M 1.92B 749M 9.73B 757M 740M 31.35B 673M 0 224M 193M 181M 165M 309M 21.16B 311M 2.14B 833M 10.82B 841M 822M 34.83B
Net income 84.8M 0 28.2M 24.26M 22.77M 20.83M 38.88M 2.67B 39.19M 269M 105M 1.36B 106M 104M 4.39B 104M 0 34.63M 29.79M 27.96M 25.58M 47.74M 3.27B 48.12M 331M 129M 1.67B 130M 127M 5.39B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
26-09-03 ILA 2,480.00 -2.25% 173,269
26-09-02 ILA 2,537.00 +2.01% 200,944
26-09-01 ILA 2,487.00 +1.51% 141,995
26-08-31 ILA 2,450.00 -1.49% 91,012
26-08-28 ILA 2,487.00 +2.43% 59,170
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock